New drug combo targets Hard-to-Treat lung cancer

NCT ID NCT07549061

Not yet recruiting Disease control Sponsor: Shanghai Chest Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a new drug called vebreltinib combined with standard chemotherapy as a first treatment for people with advanced non-small cell lung cancer that has MET overexpression and no other known genetic drivers. The study will enroll 19 participants to see if the combination shrinks tumors and controls the disease. It aims to find a better option for this specific group of lung cancer patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Vebreltinib (a targeted drug) combined with platinum-based chemotherapy
What this could lead to: If successful, this could offer a new first-line treatment option for people with a specific type of advanced lung cancer that has MET overexpression.
What could go wrong: This is a small, early-phase trial with only 19 participants, so results may not apply to everyone. The drug combination may cause side effects or not work better than standard chemo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG NEOPLASMS

Contacts and locations

Locations

241 West Huaihai Road, Xuhui District, Shanghai, 200030, China.

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.